RXRX WACC: 13.29% for Recursion Pharmaceuticals, Inc. Class A Common Stock
Current inputs imply a 13.25% cost of equity and a 31.16% pre-tax cost of debt. Use this discount rate as a starting point for DCF validation.
WACC Calculator
Values are automatically populated from real data. You can adjust them manually if needed.
Please enter a valid company ticker to calculate WACC
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) WACC in context
Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) currently screens with an estimated WACC of 13.29%. That blends a 13.25% cost of equity, a 31.16% pre-tax cost of debt, and a 99.79% equity weight into the discount rate you would typically use in a DCF model.
screens as a relatively high discount rate, which makes valuation more sensitive to execution and capital structure risk.
A 13.29% discount rate screens as a relatively high discount rate, which makes valuation more sensitive to execution and capital structure risk.
This page combines CAPM-based cost of equity with SEC-derived debt and capital structure inputs. The current beta is 2.39 and equity accounts for 99.79% of capital.
Validate business quality on the company page, then carry the same discount-rate assumptions into the DCF page to test fair value sensitivity.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.